Stockholm, October 30th / PRNewswire / -- BioArctic AB (Nasdaq Stockholm: BIOA B) announced today the composition of its 2027 Annual General Meeting of Shareholders Nomination Committee.
The nomination committee is established in accordance with the principles approved by the annual general meeting of shareholders and is composed of representatives of the three largest shareholders calculated based on voting rights as of September 30, 2026, as well as the chairman of the board of directors (the convener).
Members of the nomination committee are as follows:
- Margareta Ö hrvall, appointed by Demban AB
- Effective from Gellerfors, appointed by Ackelsta AB.
- Thomas Ehlin, Chairman of the Nomination Committee, representing Fj ä rde AP-fonden
As of September 30, 2026, the shareholders represented by the nomination committee hold approximately 57% of the company's shares and 82% of the voting rights.
The guidelines for the Nomination Committee can be found on the BioArctic website: www.bioarctic.com / en / governance / nomination-committee /
The proposals of the Nomination Committee will be announced in the notice of the 2027 annual general meeting of shareholders, and will also be published on the company's website www.bioarctic.com.
Shareholders who wish to submit proposals to the Nomination Committee may do so by email to [ email protected ] (please indicate “ Nomination Committee ” in the email), or by mail to: BioArctic AB, Att, Nomination Committee, Warfvinges, SE-112 51, Stockholm, Sweden. To ensure that the proposals are considered by the Nomination Committee, they must be received no later than January 15, 2027.
The 2027 Annual General Meeting of Shareholders will be held on Thursday, May 27, 2027, at 4:30 PM ( CEST ) in Stockholm. Requests to have certain matters discussed at the meeting must be received no later than April 15, 2027, in order to be included in the meeting notice.
The above information was released on October 30, 2026, at 3 p.m. Central European Time, through the following contact person, for public disclosure.
For further information, please contact:
Oskar Bosson, Chief Investor Relations and Communications Officer
Email: [ email protected ]Telephone: +46 704 107 180Jenny Ljunggren, External Communications and Investor Relations Manager
Email: [ email protected ]Telephone: +46 76 013 86 08About BioArctic AB
BioArctic AB ( publ ) is a Swedish research-based biopharmaceutical company focused on innovative therapies that can slow down or prevent the progression of neurodegenerative diseases. The company has invented Leqembi ® ( lecanemab ), the world's first drug proven to slow the progression of early-stage Alzheimer's disease and reduce cognitive impairment. Leqembi was jointly developed by BioArctic and its partner Eisai, with Eisai responsible for global regulatory communications and commercialization. In addition to Leqembi, BioArctic also has a broad pipeline of research and development projects, including antibodies for Parkinson's-related diseases and ALS, as well as other projects for Alzheimer's disease. Several of these projects utilize the company's proprietary BrainTransporter ™ technology, which is expected to actively deliver therapies across the blood-brain barrier to enhance treatment effectiveness. The B shares of BioArctic ( BIOA B ) are listed on the Nasdaq Stockholm Large Cap market. For more information, please visit www.bioarctic.com.
Provided by Cision: http :// news.cision.com
https :// news.cision.com / bioarctic /r/ bioarctic-s-nomination-committee-appointed , c4417898
Downloadable file: SOURCE BioArctic
